logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Therion Biologics Corporation

Calculating rank
USPTO Granted Patents = 15


Forward Citations = 285

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Dennis L Panicali (13 out of 31 patents)

silverMedal Linda R Gritz (9 out of 19 patents)

bronzeMedal Gail P Mazzara (7 out of 13 patents)

4.  Bryan E Roberts (5 out of 10 patents)

5.  Virginia Stallard (5 out of 6 patents)

6.  Jeffrey Schlom (3 out of 85 patents)

7.  Anna Mahr (3 out of 3 patents)

8.  Lendon G Payne (2 out of 8 patents)

9.  Judith A Kantor (1 out of 18 patents)

10.  Steven A Rosenberg (1 out of 150 patents)

11.  Donald W Kufe (1 out of 61 patents)

12.  Lawrence K Cohen (1 out of 1 patent)

13.  Antonia T Destree (1 out of 1 patent)

14.  Patricia Greenhalgh (5 patents)

15.  Mark Parrington (14 patents)


15 patents:

1. 7118738 - Recombinant pox virus for immunization against MUC1 tumor-associated antigen (2006-10-10),
2. 6165460 - Generation of immune responses to prostate-specific antigen (PSA) (2000-12-26),
3. 6051410 - Self-assembled, defective, nonself-propagating viral particles (2000-04-18),
4. 6001349 - Generation of human cytotoxic T-cells specific for carcinoma (1999-12-14),
5. 5905040 - Parvovirus empty capsids (1999-05-18),
6. 5858726 - Self-assembling replication defective hybrid virus particles (1999-01-12),
7. 5804196 - Self assembled, defective, nonself-propagating viral particles (1998-09-08),
8. 5747324 - Self-assembled, defective, non-self-propagating lentivirus particles (1998-05-05),
9. 5736368 - Self assembled defective non-self propagating lentiviral particles (1998-04-07),
10. 5691170 - Generation of hybrid genes and proteins by virus-mediated recombination (1997-11-25),
11. 5656465 - Methods of in vivo gene delivery (1997-08-12),
12. 5631154 - Self assembled, defective, non-self-propagating lentivirus particles (1997-05-20),
13. 5420026 - Self-assembling replication defective hybrid virus particles (1995-05-30),
14. 5242829 - Recombinant pseudorabies virus (1993-09-07),
15. 5093258 - Recombinant fowlpox virus and recombination vector (1992-03-03),
Company Overview
Therion Biologics Corporation, based in Cambridge, MA, specializes in the development of innovative immunotherapies for cancer treatment. The company focuses on harnessing the power of the immune system to target and destroy cancer cells, utilizing advanced technologies in biologics and therapeutic vaccines. With a commitment to pioneering research, Therion aims to improve patient outcomes through its cutting-edge approaches in the field of oncology, contributing to the evolving landscape of cancer therapeutics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#169 in Cambridge, MA

#1,276 in Massachusetts

#21,068 in US

#39,959 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Therion Biologics Corporation

Forward Citations = 285

13 inventors:

goldMedal Dennis L Panicali (13 out of 31 patents)

silverMedal Linda R Gritz (9 out of 19 patents)

bronzeMedal Gail P Mazzara (7 out of 13 patents)

4.  Bryan E Roberts (5 out of 10 patents)

5.  Virginia Stallard (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Therion Biologics Corporation. Retrieved from https://idiyas.com/company/therion-biologics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…